Minerva Neurosciences (NASDAQ:NERV) Shares Pass Below Two Hundred Day Moving Average of $4.54

Minerva Neurosciences, Inc. (NASDAQ:NERV) shares passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $4.54 and traded as low as $3.06. Minerva Neurosciences shares last traded at $3.14, with a volume of 5,050 shares changing hands.

Analysts Set New Price Targets

NERV has been the subject of several analyst reports. HC Wainwright cut their target price on shares of Minerva Neurosciences from $11.00 to $7.00 and set a “neutral” rating for the company in a research note on Thursday, May 2nd. StockNews.com started coverage on shares of Minerva Neurosciences in a research report on Friday. They issued a “sell” rating for the company.

Minerva Neurosciences Trading Up 1.9 %

The business has a 50 day simple moving average of $2.83 and a two-hundred day simple moving average of $4.54. The company has a market cap of $21.95 million, a PE ratio of -0.70 and a beta of 0.15.

Minerva Neurosciences (NASDAQ:NERV) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($1.13) earnings per share for the quarter, topping the consensus estimate of ($1.20) by $0.07. On average, equities research analysts expect that Minerva Neurosciences, Inc. will post -1.89 earnings per share for the current fiscal year.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.